Neuphoria Therapeutics Inc. (NEUP) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Neuphoria Therapeutics Inc. on May 21, 2026. The filing discloses a revenue distribution event related to the Company's historical participation in the Cancer Therapeutics Cooperative Research Centre (CTx CRC), which concluded in December 2020 and evolved into Canthera Discovery.
Key Financial Metrics
- Revenue Distribution: Received AUD $1.416 million on May 21, 2026.
- Trigger Event: Initiation of dosing of the first subject in the first Phase III Clinical Trial for ER+/HER2-metastatic breast cancer under the KAT6 program licensed to Pfizer Inc.
- Total Historical Distributions: AUD $3,522,413.68 received since 2016.
- Future Potential: Neuphoria estimates eligibility for approximately 4.65% of future milestone payments from CTx CRC, with a total estimated value of USD $460 million across all 17 parties.
- Other Metrics: The filing does not provide data on operating profit, cash flow, margins, debt, or liquidity.
Material Changes and Historical Context
The filing details a history of revenue distributions from the CTx CRC based on licensing activities with partners such as MSD and Pfizer. Recent distributions prior to the current event include:
- 2024: AUD $23,717 (PRMT5 target).
- 2026 (Prior to May): AUD $120,298 (FAK target).
- 2026 (Current Event): AUD $1,416,026 (KAT6 target).
The current payment represents a significant increase compared to the declining trend of distributions observed from 2020 through 2024.
Outlook, Risks, and Management Commentary
Management notes that as a passive party, the Company cannot determine if future milestones will be achieved or the size of any future payments. The filing includes standard forward-looking statement disclaimers, cautioning that actual results may differ materially from expectations due to risks and uncertainties. There is no specific financial guidance provided for the Company's core operations.
Key Facts for Investor Verification
- Verify the exchange rate impact of the AUD $1.416 million payment on the Company's USD financial statements.
- Confirm the status of the Phase III Clinical Trial for the KAT6 program in ER+/HER2-metastatic breast cancer.
- Assess the likelihood of achieving future milestones within the CTx CRC portfolio given the Company's passive role.
- Review the Company's overall cash position to determine if this distribution is a material component of its liquidity.